Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy

Keyphrases

• Checkpoint Immunotherapy 100%
• Metastatic Melanoma 100%
• Viable Pregnancy 100%
• During Pregnancy 50%
• Pregnancy Outcome 50%
• T Cells 50%
• Immune Tolerance 50%
• Mechanism of Action 50%
• Allograft 50%
• Metastatic Tumor 50%
• Tumor Progression 50%
• Checkpoint Inhibitors 50%
• Cancer in Pregnancy 50%
• Combination Immunotherapy 50%
• Treatment Alternatives 50%
• Risk of Miscarriage 50%
• Oncological Outcomes 50%
• Immune-related Adverse Events 50%
• Metastatic Cancer 50%
• Nivolumab Plus Ipilimumab 50%
• Immune-related Adverse Effects 50%
• Checkpoint Pathway 50%

Medicine and Dentistry

• Immunotherapy 100%
• Metastatic Melanoma 100%
• Metastatic Carcinoma 66%
• Spontaneous Abortion 33%
• T Cell 33%
• Immunological Tolerance 33%
• Allograft 33%
• Tumor Progression 33%
• Side Effect 33%
• Ipilimumab 33%
• Nivolumab 33%
• Immune-Related Adverse Events 33%